As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of caplacizumab within its marketing authorisation
for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.
The timelines for this appraisal are still to be confirmed following a recent update from Ablynx related to Sanofi’s previously announced tender offers to acquire all of the outstanding shares (including shares represented by American Depositary Shares, warrants and convertible bonds) of Ablynx. Please refer to link for further information http://www.ablynx.com/uploads/data/files/press%20release_sanofi%20squeez%20out_14%20may%202018_eng_final.pdf
NICE is monitoring the situation and will update interested parties as and when further information is available.